{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=PD",
    "query": {
      "condition": "PD"
    },
    "page_size": 10
  },
  "pagination": {
    "page": 1,
    "page_size": 10,
    "total_count": 1513,
    "total_pages": 152,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=PD&page=2&page_size=10",
    "previous_page_url": null
  },
  "source": "remote",
  "last_synced_at": "2026-06-26T04:58:54.544Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT04736173",
      "title": "Study Evaluating Effectiveness and Safety of Zimberelimab and Domvanalimab in Lung Cancer",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Non Small Cell Lung Cancer",
        "Nonsquamous Non Small Cell Lung Cancer",
        "Squamous Non Small Cell Lung Cancer",
        "Lung Cancer"
      ],
      "interventions": [
        {
          "name": "Domvanalimab",
          "type": "DRUG"
        },
        {
          "name": "Zimberelimab",
          "type": "DRUG"
        },
        {
          "name": "Carboplatin",
          "type": "DRUG"
        },
        {
          "name": "Paclitaxel",
          "type": "DRUG"
        },
        {
          "name": "Pemetrexed",
          "type": "DRUG"
        },
        {
          "name": "Pembrolizumab",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Arcus Biosciences, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 169,
      "start_date": "2021-02-08",
      "completion_date": "2027-05",
      "has_results": false,
      "last_update_posted_date": "2026-06-01",
      "last_synced_at": "2026-06-26T04:58:54.544Z",
      "location_count": 3,
      "location_summary": "Columbus, Georgia • Kingwood, Texas • Blacksburg, Virginia",
      "locations": [
        {
          "city": "Columbus",
          "state": "Georgia"
        },
        {
          "city": "Kingwood",
          "state": "Texas"
        },
        {
          "city": "Blacksburg",
          "state": "Virginia"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04736173"
    },
    {
      "nct_id": "NCT05785767",
      "title": "A Study to Learn if a Combination of Fianlimab and Cemiplimab Versus Cemiplimab Alone is More Effective for Adult Participants With Advanced Non-Small Cell Lung Cancer (NSCLC)",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2",
        "PHASE3"
      ],
      "conditions": [
        "Advanced Non-Small Cell Lung Cancer"
      ],
      "interventions": [
        {
          "name": "fianlimab",
          "type": "DRUG"
        },
        {
          "name": "cemiplimab",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Regeneron Pharmaceuticals",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 850,
      "start_date": "2023-06-30",
      "completion_date": "2032-02-05",
      "has_results": false,
      "last_update_posted_date": "2026-01-22",
      "last_synced_at": "2026-06-26T04:58:54.544Z",
      "location_count": 23,
      "location_summary": "Tucson, Arizona • Yuma, Arizona • Redlands, California + 20 more",
      "locations": [
        {
          "city": "Tucson",
          "state": "Arizona"
        },
        {
          "city": "Yuma",
          "state": "Arizona"
        },
        {
          "city": "Redlands",
          "state": "California"
        },
        {
          "city": "Norwich",
          "state": "Connecticut"
        },
        {
          "city": "Clermont",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05785767"
    },
    {
      "nct_id": "NCT04929041",
      "title": "Testing the Addition of Radiation Therapy to the Usual Treatment (Immunotherapy With or Without Chemotherapy) for Advanced Stage Non-small Cell Lung Cancer Patients Who Are PD-L1 Negative",
      "overall_status": "SUSPENDED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2",
        "PHASE3"
      ],
      "conditions": [
        "Lung Adenocarcinoma",
        "Lung Adenosquamous Carcinoma",
        "Lung Non-Small Cell Carcinoma",
        "Stage IIIB Lung Cancer AJCC v8",
        "Stage IIIC Lung Cancer AJCC v8",
        "Stage IV Lung Cancer AJCC v8"
      ],
      "interventions": [
        {
          "name": "Biopsy Procedure",
          "type": "PROCEDURE"
        },
        {
          "name": "Biospecimen Collection",
          "type": "PROCEDURE"
        },
        {
          "name": "Computed Tomography",
          "type": "PROCEDURE"
        },
        {
          "name": "Echocardiography Test",
          "type": "PROCEDURE"
        },
        {
          "name": "Ipilimumab",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Magnetic Resonance Imaging",
          "type": "PROCEDURE"
        },
        {
          "name": "Nivolumab",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Positron Emission Tomography",
          "type": "PROCEDURE"
        },
        {
          "name": "Quality-of-Life Assessment",
          "type": "OTHER"
        },
        {
          "name": "Radiation Therapy",
          "type": "RADIATION"
        }
      ],
      "intervention_types": [
        "PROCEDURE",
        "BIOLOGICAL",
        "OTHER",
        "RADIATION"
      ],
      "sponsor": "National Cancer Institute (NCI)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 427,
      "start_date": "2022-10-07",
      "completion_date": "2030-12-12",
      "has_results": false,
      "last_update_posted_date": "2026-05-13",
      "last_synced_at": "2026-06-26T04:58:54.544Z",
      "location_count": 170,
      "location_summary": "Phoenix, Arizona • Little Rock, Arkansas • Berkeley, California + 130 more",
      "locations": [
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Little Rock",
          "state": "Arkansas"
        },
        {
          "city": "Berkeley",
          "state": "California"
        },
        {
          "city": "Duarte",
          "state": "California"
        },
        {
          "city": "Irvine",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04929041"
    },
    {
      "nct_id": "NCT04728295",
      "title": "Evaluation of the Safety and Effectiveness of Bilateral Exablate Ablation of the Pallidothalamic Tract (PTT) for the Treatment of the Motor Complications of Parkinson's Disease (PD)",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Parkinson Disease"
      ],
      "interventions": [
        {
          "name": "Exablate 4000",
          "type": "DEVICE"
        }
      ],
      "intervention_types": [
        "DEVICE"
      ],
      "sponsor": "InSightec",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "30 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "30 Years and older"
      },
      "enrollment_count": 50,
      "start_date": "2021-05-14",
      "completion_date": "2028-12-01",
      "has_results": false,
      "last_update_posted_date": "2025-02-17",
      "last_synced_at": "2026-06-26T04:58:54.544Z",
      "location_count": 6,
      "location_summary": "Palo Alto, California • Delray Beach, Florida • Chicago, Illinois + 2 more",
      "locations": [
        {
          "city": "Palo Alto",
          "state": "California"
        },
        {
          "city": "Delray Beach",
          "state": "Florida"
        },
        {
          "city": "Chicago",
          "state": "Illinois"
        },
        {
          "city": "Baltimore",
          "state": "Maryland"
        },
        {
          "city": "New York",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04728295"
    },
    {
      "nct_id": "NCT04428151",
      "title": "Lenvatinib (E7080/MK-7902) in Combination With Pembrolizumab (MK-3475) vs. Standard Chemotherapy and Lenvatinib Monotherapy in Participants With Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma That Progressed After Platinum Therapy and Immunotherapy (MK-7902-009/E7080-G000-228/LEAP-009)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Squamous Cell Carcinoma of Head and Neck"
      ],
      "interventions": [
        {
          "name": "Lenvatinib",
          "type": "DRUG"
        },
        {
          "name": "Pembrolizumab",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Docetaxel",
          "type": "DRUG"
        },
        {
          "name": "Capecitabine",
          "type": "DRUG"
        },
        {
          "name": "Paclitaxel",
          "type": "DRUG"
        },
        {
          "name": "Cetuximab",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG",
        "BIOLOGICAL"
      ],
      "sponsor": "Merck Sharp & Dohme LLC",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 408,
      "start_date": "2020-08-06",
      "completion_date": "2025-10-30",
      "has_results": true,
      "last_update_posted_date": "2025-12-04",
      "last_synced_at": "2026-06-26T04:58:54.544Z",
      "location_count": 55,
      "location_summary": "Duarte, California • Los Angeles, California • New Haven, Connecticut + 47 more",
      "locations": [
        {
          "city": "Duarte",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "New Haven",
          "state": "Connecticut"
        },
        {
          "city": "Washington D.C.",
          "state": "District of Columbia"
        },
        {
          "city": "Gainesville",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04428151"
    },
    {
      "nct_id": "NCT07221253",
      "title": "A Study of Rilvegostomig or Durvalumab Plus Chemotherapy for First-Line Treatment of Biliary Tract Cancer (ARTEMIDE-Biliary02)",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Biliary Tract Cancer"
      ],
      "interventions": [
        {
          "name": "Rilvegostomig",
          "type": "DRUG"
        },
        {
          "name": "Durvalumab",
          "type": "DRUG"
        },
        {
          "name": "Gemcitabine/Cisplatin",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "AstraZeneca",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 1100,
      "start_date": "2025-12-04",
      "completion_date": "2029-07-31",
      "has_results": false,
      "last_update_posted_date": "2026-06-18",
      "last_synced_at": "2026-06-26T04:58:54.544Z",
      "location_count": 36,
      "location_summary": "Birmingham, Alabama • Phoenix, Arizona • Tucson, Arizona + 27 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Tucson",
          "state": "Arizona"
        },
        {
          "city": "Duarte",
          "state": "California"
        },
        {
          "city": "Orange",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07221253"
    },
    {
      "nct_id": "NCT04155645",
      "title": "To Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AZD8233 After Multiple Dose Administration in Subjects With Dyslipidemia",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Dyslipidemia"
      ],
      "interventions": [
        {
          "name": "AZD8233 subcutaneous injection",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "AstraZeneca",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "18 Years to 65 Years"
      },
      "enrollment_count": 34,
      "start_date": "2019-11-21",
      "completion_date": "2021-06-07",
      "has_results": false,
      "last_update_posted_date": "2021-06-30",
      "last_synced_at": "2026-06-26T04:58:54.544Z",
      "location_count": 7,
      "location_summary": "Chula Vista, California • Glendale, California • La Mesa, California + 4 more",
      "locations": [
        {
          "city": "Chula Vista",
          "state": "California"
        },
        {
          "city": "Glendale",
          "state": "California"
        },
        {
          "city": "La Mesa",
          "state": "California"
        },
        {
          "city": "Jacksonville",
          "state": "Florida"
        },
        {
          "city": "Orlando",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04155645"
    },
    {
      "nct_id": "NCT02395172",
      "title": "Avelumab in Non-Small Cell Lung Cancer (JAVELIN Lung 200)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Carcinoma, Non-Small-Cell Lung"
      ],
      "interventions": [
        {
          "name": "Avelumab",
          "type": "DRUG"
        },
        {
          "name": "Docetaxel",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "EMD Serono Research & Development Institute, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 792,
      "start_date": "2015-03-24",
      "completion_date": "2019-12-03",
      "has_results": true,
      "last_update_posted_date": "2020-08-03",
      "last_synced_at": "2026-06-26T04:58:54.544Z",
      "location_count": 27,
      "location_summary": "Tuscaloosa, Alabama • Scottsdale , Phoenix, Arizona • Anaheim, California + 24 more",
      "locations": [
        {
          "city": "Tuscaloosa",
          "state": "Alabama"
        },
        {
          "city": "Scottsdale , Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Anaheim",
          "state": "California"
        },
        {
          "city": "Lawndale",
          "state": "California"
        },
        {
          "city": "Modesto",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02395172"
    },
    {
      "nct_id": "NCT07398157",
      "title": "Simplified, Scalable, 24-hour Adaptive DBS in Parkinson's Disease",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "PD - Parkinson's Disease"
      ],
      "interventions": [
        {
          "name": "Medtronic Percept Deep Brain Stimulation (cDBS)",
          "type": "DEVICE"
        },
        {
          "name": "Medtronic Percept Deep Brain Stimulation (daytime aDBS)",
          "type": "DEVICE"
        },
        {
          "name": "Medtronic Percept Deep Brain Stimulation (nighttime aDBS)",
          "type": "DEVICE"
        }
      ],
      "intervention_types": [
        "DEVICE"
      ],
      "sponsor": "University of California, San Francisco",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 24,
      "start_date": "2026-04-09",
      "completion_date": "2031-11-30",
      "has_results": false,
      "last_update_posted_date": "2026-05-05",
      "last_synced_at": "2026-06-26T04:58:54.544Z",
      "location_count": 1,
      "location_summary": "San Francisco, California",
      "locations": [
        {
          "city": "San Francisco",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07398157"
    },
    {
      "nct_id": "NCT05984277",
      "title": "A Global Study of Volrustomig (MEDI5752) Plus Chemotherapy Versus Pembrolizumab Plus Chemotherapy for Participants With Metastatic Non-small Cell Lung Cancer.",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Metastatic Non-small Cell Lung Cancer"
      ],
      "interventions": [
        {
          "name": "Volrustomig",
          "type": "DRUG"
        },
        {
          "name": "Pembrolizumab",
          "type": "DRUG"
        },
        {
          "name": "Carboplatin",
          "type": "DRUG"
        },
        {
          "name": "Paclitaxel",
          "type": "DRUG"
        },
        {
          "name": "Pemetrexed",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "AstraZeneca",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 1200,
      "start_date": "2023-10-24",
      "completion_date": "2029-03-23",
      "has_results": false,
      "last_update_posted_date": "2026-03-17",
      "last_synced_at": "2026-06-26T04:58:54.544Z",
      "location_count": 41,
      "location_summary": "Prescott, Arizona • Hot Springs, Arkansas • Springdale, Arkansas + 36 more",
      "locations": [
        {
          "city": "Prescott",
          "state": "Arizona"
        },
        {
          "city": "Hot Springs",
          "state": "Arkansas"
        },
        {
          "city": "Springdale",
          "state": "Arkansas"
        },
        {
          "city": "Long Beach",
          "state": "California"
        },
        {
          "city": "Lone Tree",
          "state": "Colorado"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05984277"
    }
  ]
}